Swiss National Bank Tcr2 Therapeutics Inc. Transaction History

Swiss National Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$4.58 - $8.34 $249,610 - $454,530	-54,500 Closed	0 $0
Q2 2021 Aug 06, 2021	BUY	$16.41 - $24.71 $34,461 - $51,891	2,100 Added 4.01%	54,500 $894,000
Q1 2021 May 07, 2021	BUY	$20.38 - $34.07 $146,736 - $245,304	7,200 Added 15.93%	52,400 $1.16 Million
Q4 2020 Feb 05, 2021	BUY	$19.0 - $32.63 $858,800 - $1.47 Million	45,200 New	45,200 $1.4 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.